Climb Bio reported a Q4 2025 net loss of USD 17.5 million and a FY 2025 net loss of USD 59.9 million. Q4 R&D expenses were USD 13.7 million (up 130.6%) and Q4 G&A expenses were USD 5.6 million (up 12.2%), while FY 2025 R&D expenses were USD 46.7 million (up 225.9%) and FY 2025 G&A expenses were USD 21.2 million (up 32.1%). Other income, net was USD 1.8 million in Q4 2025 (down 28.7%) and USD 8.0 million in FY 2025 (down 1.1%). Cash, cash equivalents and marketable securities totaled USD 160.7 million as of Dec. 31, 2025, which Climb Bio said is expected to fund operations into 2028. On the business side, Climb Bio said dosing is complete in a Phase 1 healthy-volunteer study of a subcutaneous formulation of budoprutug, with data expected in H1 2026. The company said enrollment is ongoing in its budoprutug trials in primary membranous nephropathy, immune thrombocytopenia and systemic lupus erythematosus, with initial data from all three studies expected in H2 2026; it also expects first patient dosed in a China SLE study in H1 2026. For CLYM116, Climb Bio said enrollment is ongoing in a Phase 1 healthy-volunteer study, with initial data expected mid-2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603050700PRIMZONEFULLFEED9666043) on March 05, 2026, and is solely responsible for the information contained therein.
Comments